Global Chlamydia Infection Diagnostics Market - 2024-2031

Global Chlamydia Infection Diagnostics Market - 2024-2031

Global Chlamydia Infection Diagnostics Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031

Chlamydia is a common sexually transmitted infection (STI) caused by bacteria. Chlamydia infections are treatable and curable. However, its symptoms are often unnoticeable. It’s important to receive treatment for chlamydia as soon as possible. Left untreated, chlamydia can lead to serious complications and cause permanent damage to your reproductive organs.

Market Dynamics: Drivers & Restraints

Rise in government initiatives

Government initiatives, such as the National Chlamydia Screening Program (NCSP) in the UK, further drive the market's growth. These initiatives target high-risk individuals, focusing on rapid treatment and expanded testing in community settings.

However, privacy concerns and societal stigma surrounding STD testing limit market growth, as individuals may be hesitant to undergo testing due to these factors. Despite these challenges, the high prevalence, growing awareness of early detection and treatment, and advancements in diagnostic technologies continue to drive the expansion of the market.



Lack of knowledge of chlamydia diagnostic tests in low and middle-income countries



The chlamydia infection diagnostics market faces challenges in low and middle-income countries due to lack of knowledge, stigma associated with voluntary screening, and negative social perception of sexually transmitted diseases (STDs). This leads to undiagnosed infections and limits the market's growth due to concerns about privacy and social status.



For more details on this report – Request for Sample

Segment Analysis

The global chlamydia infection diagnostics market is segmented based on test type, infection Type, end-user and region.

The Nucleic Acid Amplification Test (NAAT) from the test type segment accounted for approximately 47.3% of the chlamydia infection diagnostics market share

The Nucleic Acid Amplification Test (NAAT) from the test type segment accounted for approximately 42.3%. The Nucleic Acid Amplification Test (NAAT) is the most recommended method for diagnosing and monitoring chlamydia trachomatis infection. This molecular test detects DNA, the genetic material of the disease, in biological samples. It is more sensitive and specific than other tests and can be performed on vaginal swabs and urine from both men and women, eliminating the need for a pelvic exam in women.

For instance, in March 2022, the United States Food and Drug Administration (FDA) announced that it would allow the Binx Health IO CT/N assay at point-of-care settings in physician offices, community-based clinics, urgent care settings, and other end users.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like the FDA grants, high prevalence of chlamydia infection among individuals and new product developments by the key players and others help the region to have highest market share during the forecast period.

For instance, in November 2023, the U.S. Food and Drug Administration granted marketing authorization to LetsGetChecked for the Simple 2 Test. This is the first diagnostic test for chlamydia and gonorrhea with at-home sample collection to be granted marketing authorization. Prior to the authorization, the only cleared tests for either condition were used with samples collected at the point of care, such as a doctor’s office.

Market Segmentation

By Test Type
• Nucleic Acid Amplification Test (NAAT)
• Culture Tests
• Direct Fluorescent Antibody Test
• Serology Tests
• Others

By Infection Type
• Genital Chlamydia Infection
• Rectal Chlamydia Infection
• Ocular Chlamydia Infection

By End-User
• Hospitals
• Diagnostic Centers
• Specialty Clinics
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Bio-Rad Laboratories, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Hologic, Inc., Quidel Corporation, DiaSorin SpA, Becton, Dickinson and Company, Danaher Corporation (Cepheid), Savyon Diagnostics Ltd, Trinity Biotech Plc among others.

Key Developments

 In May 2024, Sherlock Biosciences enrolled its first patient in the PROMISE trial which evaluates the company’s rapid over-the-counter (OTC) test for sexually transmitted infections (STIs). The molecular test analyses DNA and RNA which is self-collected through penile meatal or vaginal swabs to test for the presence of chlamydia trachomatis and Neisseria gonorrhoea.

 In March 2023, The Food and Drug Administration (FDA) cleared the Visby Medical Sexual Health Test, a polymerase chain reaction (PCR) diagnostic test for the detection of sexually transmitted infections (STIs) caused by Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in women.



Why Purchase the Report??
• To visualize the global chlamydia infection diagnostics market segmentation based on test type, infection type, end user and region as well as understand key commercial assets and players.
• identify commercial opportunities by analyzing trends and co-development.
• excel data sheet with numerous data points of the chlamydia infection diagnostics market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global chlamydia infection diagnostics market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies